RESUMO
Objective:To analyze the monitoring results of coal-burning-borne arsenic poisoning in Xiangyang City, Hubei Province from 2014 to 2018.Methods:In 2014-2018, according to "the Monitoring Plan for Coal-burning-borne Endemic Arsenic Poisoning in Hubei Province", five villages in Xiangyang City were selected as monitoring sites every year. Coal samples from 8 households were collected by four-point method after multi-point sampling and mixing in each site every year, coal arsenic content was detected. Urine samples of 10 adults (half male and half female) were collected to detect the arsenic content in urine. The disease condition of residents with coal-burning-borne arsenic poisoning was surveyed.Results:From 2014 to 2018, there was a significant difference in coal arsenic content ( F=21.572, P < 0.05), and the coal arsenic content in 2018 was significantly lower than those in other years ( P < 0.05); there was no significant difference in arsenic content in adult urine (χ 2=1.647, P > 0.05). During the past five years, 266 suspected cases, 736 mild cases, 633 moderate cases and 18 severe cases were detected. There was no significant difference in the detection rates of arsenic poisoning among different years (χ 2=1.094, P > 0.05). Conclusions:The detection rate of coal-burning-borne arsenic poisoning in Xiangyang City from 2014 to 2018 is relatively stable, and the management of high arsenic coal has achieved initial results. It is necessary to further strengthen disease monitoring, energy diversification transformation and health education of residents, so as to further improve the prevention and management mechanism of coal-burning-borne arsenic poisoning.
RESUMO
OBJECTIVE:To observe the clinical efficacy and safety of leflunomide combined with prednisone in the treatment of polymyositis. METHODS:Totally 98 polymyositis patients in our hospital were divided into observation group and control group by random number table,49 cases in each group. Control group received Prednisone tablet with initial dose of 60-100 mg/d,tid, then gradually reduced to maintaining dose of 10 mg/d,tid,based on patients'improvement of creatine kinase(CK)and clinical symptoms. Observation group was additionally given Leflunomide tablet 10 mg,bid,based on the control group. They all treated for 120 d. Clinical efficacy,muscle strength evaluation,muscle enzymes [including CK,lactate dehydrogenase(LDH),aspartate aminotransferase(AST),creatine phosphokinase(CPK),alanine aminotransferase(ALT)] and serum inflammatory factors(includ-ing IL-2,IL-8,IL-12,TNF-α,hs-CRP)before and after treatment in 2 groups were observed,the incidence of adverse reactions in 2 groups was recorded. RESULTS:After treatment,the total effective rate(87.8% vs. 75.5%)and muscle strength achieving grade 3(81.6% vs. 55.1%)in observation group were significantly higher than control group,and the total adverse reaction rate (12.2% vs. 22.4%)was lower than control,with statistically significances(P<0.05). After treatment,the muscle enzymes and se-rum inflammatory factor levels in groups were significantly lower than before,and observation group was lower than control group,with statistically significances(P<0.05). CONCLUSIONS:Leflunomide combined with prednisone shows good efficacy in the treatment of polymyositis,it can significantly improve the muscle strength,muscle enzymes and serum inflammatory factor lev-els,and dose not increase the incidence of adverse reactions,with good safety.
